FAQ

Depsipeptide Antineoplastic Antibiotic

Known as: Depsipeptide 
A bicyclic peptide antibiotic with one or more amide bonds replaced by ester bonds. Depsipeptide antibiotics act as histone deacetylase inhibitors… (More)

Topic mentions per year

Topic mentions per year

1963-2016
024619632016

Related topics

Related topics

2 relations

Broader (1)

Depsipeptides

Narrower (1)

romidepsin

Related mentions per year

Related mentions per year

1963-2018
1960198020002020
Depsipeptide Antineoplastic Antibiotic
romidepsin
Depsipeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis.
Chronic lymphocytic leukemia (CLL) is an incurable disease characterized by failure of mature lymphocytes to undergo apoptosis… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
PURPOSE Epigenetic modulation of gene expression plays an important role in cancer, including leukemia. Furthermore, histone… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2007
2007
HDAC inhibitors overcome first hurdle
The approval by the US Food and Drug Administration (FDA) of the first histone deacetylase (HDAC) inhibitor in October went… (More)
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.
PURPOSE This phase II study was undertaken to assess objective response and toxicity of histone deacetylase inhibitor… (More)
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2006
2006
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
PURPOSE Histone acetyltransferases and histone deacetylases (HDAC) control the acetylation state of histones and other proteins… (More)
Is this relevant?
2006
2006
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
PURPOSE To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetic profile, and… (More)
Is this relevant?
2004
2004
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
BACKGROUND Immune-compromised individuals are at increased risk for developing aggressive Epstein-Barr virus (EBV)-associated… (More)
Is this relevant?
2004
2004
Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates
Acetylation of histones by histone acetyl transferases (HATs) leads to transcriptional activation, while histone deacetylase… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.
Depsipeptide (FR901228) is a bicyclic peptide isolated from Chromobacterium violaceum that has demonstrated potent in vitro… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.
Therapy of B-cell chronic lymphocytic leukemia (CLL) has been limited by both the nonselectivity of therapeutic agents toward… (More)
Is this relevant?